Cancer Genetics Focus::Myeloid

Cancer Genetics has introduced Focus::Myeloid, a comprehensive next-generation sequencing-based panel for the diagnosis, prognosis, and clinical management of myeloid cancer patients, including those with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. Utilizing Illumina NGS, the panel assesses 54 clinically relevant genes. Sanger sequencing is performed to assess abnormalities in several additional genes to provide a precise evaluation of the genetic profile of each patient's cancer, the company said. Focus::Myeloid is performed in CGI's CLIA certified lab, and is available as an individual test and as part of the company's complete programs for AML, MDS, and MPN, which offer a comprehensive assessment of the molecular genetics of the cancer along with pathology and morphological information.